Sandoz
506 Carnegie Center Drive, Suite 400
Princeton
New Jersey
08540
United States
Tel: 609-627-8500
Fax: 609-627-8683
Website: http://www.us.sandoz.com/
161 articles about Sandoz
-
Sandoz launches Hyrimoz® (adalimumab) high-concentration formulation in Europe, aiming to improve patient care
11/21/2023
Sandoz, the global leader in generic and biosimilar medicines, announces the launch of Hyrimoz® citrate-free high concentration formulation in Europe.
-
Sandoz inaugurates new antibiotic production plant in Austria and new biosimilar development center in Germany
11/10/2023
Sandoz, the global leader in generic and biosimilar medicines, has opened two new European facilities, in line with its ongoing plans to strengthen sustainable development and supply of critical medicines in Europe and beyond.
-
Sandoz successfully issues CHF 750 million in inaugural bonds
10/26/2023
Sandoz, the global leader in generic and biosimilar medicines, announced the issuance of two highly successful inaugural CHF bonds with gross proceeds of CHF 750 million.
-
Sandoz reports year-to-date sales for the first nine months of 2023
10/24/2023
Sandoz, the global leader in generic and biosimilar medicines, announced its year-to-date sales for the first nine months of 2023, with net sales up 6 percent in constant currencies to reach USD 7.1 billion.
-
Sandoz enters new era as standalone global leader and European champion in generic and biosimilar medicines
10/4/2023
Sandoz, the global leader in generic and biosimilar medicines, celebrates the start of share trading on the SIX Swiss Exchange as an independent company.
-
The Swiss pharma’s shareholders on Friday approved spinning off the generics and biosimilars division, with plans to launch at least five additional biologic drugs.
-
In the largest biotech Series C financing so far this year, Generate:Biomedicines raised $273 million, while Neumora and RayzeBio announced IPO pricing valued at more than $560 million combined.
-
As the Novartis generics and biosimilars division nears its spin-off, Sandoz has signed a commercialization agreement with Samsung Bioepis, gaining rights to the latter’s Stelara biosimilar.
-
A second trial shows Novo Nordisk’s Wegovy improves heart health. Meanwhile, many other drugs are beginning to face generic competition, including from newly approved biosimilars.
-
Amid one of the industry’s steepest patent cliffs, the regulator Thursday approved Sandoz’s Tyruko, the first biosimilar for treating relapsing multiple sclerosis in adults. Sandoz is a division of Novartis.
-
AbbVie’s Humira will now face competition from new biosimilars, including Boehringer Ingelheim’s Cyltezo, Celltrion’s Yuflyma, Organon and Samsung’s Hadlima, and Sandoz’s Hyrimoz.
-
Novartis unveiled plans to separate its generics and biosimilars arm, Sandoz, into a standalone entity, allowing both to pursue independent and more business-appropriate growth strategies.
-
Of the 1,400 jobs Novartis plans to eliminate in Switzerland, about half will include leadership and management positions, the company reported Monday.
-
Sandoz hopes its high-concentration formulation of an already greenlit biosimilar will be approved by the time AbbVie’s blockbuster drug Humira loses patent protection in the United States.
-
Total sales for the quarter were $12.8 billion, with its innovative medicines, which include key assets, bringing in $10.8 billion.
-
Rather than selling, Novartis could spin Sandoz off into its own separate entity with its own listing on a stock exchange.
-
Sandoz launches first generic pirfenidone in US for patients with idiopathic pulmonary fibrosis, growing its respiratory portfolio
5/12/2022
Sandoz announced the US launch of its generic pirfenidone, the first AB-rated equivalent to Genentech's Esbriet®*, to treat patients with idiopathic pulmonary fibrosis.
-
Three life sciences companies, ADC Therapeutics, Longeveron and Adimab, are undertaking leadership transitions with the announcements of new chief executive officers.
-
Novartis’ Sandoz business unit saw a strong financial performance in the first quarter of 2022, with overall sales growth of 8%, mostly outside of the United States.
-
With the accelerated approval from the U.S. Food and Drug Administration, Vijoice becomes the first treatment approved in the United States for PROS